Reduced capillary permeability and capillary density in the skin of GH-deficient adults: improvement after 12 months GH replacement

被引:22
作者
Oomen, PHN
Beentjes, JAM
Bosma, E
Smit, AJ
Reitsma, WD
Dullaart, RPF
机构
[1] Univ Groningen Hosp, Dept Internal Med, Div Gen Internal Med, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen Hosp, Dept Internal Med, Div Endocrinol, NL-9700 RB Groningen, Netherlands
关键词
D O I
10.1046/j.1365-2265.2002.01517.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE Several lines of evidence suggest that the GH-IGF-1 axis affects capillary permeability and angiogenesis. We evaluated skin capillary permeability and capillary density in GH-deficient adults, before and after GH replacement therapy. PATIENTS Seven normotensive, nondiabetic GH-deficient adults (two women) were matched with 14 control subjects. MEASUREMENTS Large-window videodensitometry with sodium fluorescein was performed in all subjects. Capillary permeability was expressed as the average relative light intensity over the first 7 min after the appearance of fluorescein in the skin capillaries; l(av)(7). Skin capillary density was determined by counting the visualized capillaries and was expressed as n/mm(2). The GH-deficient patients were restudied after 12 months of GH replacement therapy (2 U/day). RESULTS Both capillary permeability and capillary density were lower in untreated GH-deficient patients than in control subjects (median, interquartile range): I-av(7) in GH-deficient patients 47.1 (45.1-52-2)% vs. 57.5 (50.5-64.8)% in controls, P < 0.05; capillary density in GH-deficient patients 18 (12-24)/mm(2) vs. 32 (26-36)/mm(2) in controls, P < 0.05. GH treatment normalized plasma IGF-1 from 4.3 (1.0-13.4) to 22.2 (19.8-48.2) nmol/l (P < 0.05). Furthermore, both capillary permeability [I-av(7) 53.1 (48.8-58-4)%, P < 0.05] and capillary density [26 (17-34)/mm(2), P < 0.05] increased to a level that was not different from that in control subjects. CONCLUSIONS The present study demonstrates that the growth hormone deficiency syndrome is associated with microvascular alterations, which are responsive to growth hormone replacement therapy.
引用
收藏
页码:519 / 524
页数:6
相关论文
共 38 条
[1]  
Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379
[2]   Divergence between growth hormone responses to insulin-induced hypoglycaemia and growth hormone-releasing hormone in patients with non-functioning pituitary macroadenomas and hyperprolactinaemia [J].
Beentjes, JAM ;
Tjeerdsma, G ;
Sluiter, WJ ;
Dullaart, RPF .
CLINICAL ENDOCRINOLOGY, 1996, 45 (04) :391-398
[3]  
Bollinger A., 1990, Clinical Capillaroscopy
[4]   The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency [J].
Christ, ER ;
Cummings, MH ;
Westwood, NB ;
Sawyer, BM ;
Pearson, TC ;
Sonksen, PH ;
RussellJones, DL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (09) :2985-2990
[5]   RECOMBINANT HUMAN INSULIN-LIKE GROWTH-FACTOR-I INCREASES FOREARM BLOOD-FLOW [J].
COPELAND, KC ;
NAIR, KS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (01) :230-232
[6]   GROWTH-HORMONE TREATMENT IN GROWTH HORMONE-DEFICIENT ADULTS .2. EFFECTS ON EXERCISE PERFORMANCE [J].
CUNEO, RC ;
SALOMON, F ;
WILES, CM ;
HESP, R ;
SONKSEN, PH .
JOURNAL OF APPLIED PHYSIOLOGY, 1991, 70 (02) :695-700
[7]   BODY-COMPOSITION IN ADULT GROWTH HORMONE-DEFICIENT MEN, ASSESSED BY ANTHROPOMETRY AND BIOIMPEDANCE ANALYSIS [J].
DEBOER, H ;
BLOK, GJ ;
VOERMAN, HJ ;
DEVRIES, PMJM ;
VANDERVEEN, EA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (03) :833-837
[8]   CLINICAL ASPECTS OF GROWTH-HORMONE DEFICIENCY IN ADULTS [J].
DEBOER, H ;
BLOK, GJ ;
VANDERVEEN, EA .
ENDOCRINE REVIEWS, 1995, 16 (01) :63-86
[9]   Growth hormone, the insulin-like growth factor system, and the kidney [J].
Feld, S ;
Hirschberg, R .
ENDOCRINE REVIEWS, 1996, 17 (05) :423-480
[10]   Reduced retinal vascularization in children with growth hormone deficiency [J].
Hellström, A ;
Svensson, E ;
Carlsson, B ;
Niklasson, A ;
Albertsson-Wikland, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) :795-798